|
| Press Releases |
|
 |
|
| Wednesday, April 9, 2025 |
|
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
| SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
| Tuesday, April 16, 2024 |
|
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
| SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, August 14, 2023 |
|
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, June 12, 2023 |
|
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, May 22, 2023 |
|
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, December 19, 2022 |
|
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 4, 2022 |
|
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, August 24, 2022 |
|
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, July 8, 2022 |
|
|
SinoMab Received the Highest Subsidy from HKSTP |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
"Tang Vogue Beyond the Horizons: A Golden Era of Multicultural Integration and Openness" exhibition opens 
Jun 27, 2025 22:36 HKT/SGT
|
|
|
Prime Minister Paetongtarn Positions Thailand as Regional AI Ethics Leader: Official Launch of AIGPC at the UNESCO Global Forum on the Ethics of AI 2025
Jun 27, 2025 17:00 HKT/SGT
|
|
|
GA-ASI Announces Investment in Dutch Technology Innovator Arceon
Jun 27, 2025 01:00 HKT/SGT
|
|
|
IBI Announces 23-Fold Surge in Net Profit for FY2025
Jun 26, 2025 22:37 HKT/SGT
|
|
|
Wasion Wins Three Major Smart Power Meter Contracts In Emerging Overseas Markets, Total Contract Value Exceeds HK$940 million
Jun 26, 2025 20:58 HKT/SGT
|
|
|
AEON Credit Reported Rebound Growth in 1QFY2025/26, Net Profit Up 31.3% to HK$109.3 million
Jun 26, 2025 20:01 HKT/SGT
|
|
|
Regina Miracle FY25 Net Profit Up by 28.4% to HK$180 Million
Jun 26, 2025 19:19 HKT/SGT
|
|
|
On Its Centennial: The Occasion of Replacing the Kiswa of the Noble Kaaba Embodies the Kingdom of Saudi Arabia's Enduring Care for the Two Holy Mosques
Jun 26, 2025 15:00 HKT/SGT
|
|
|
World's Premier AI Conference, World AI Show - Indonesia 2025, Arrives in Jakarta to Power Southeast Asia's AI Revolution
Jun 26, 2025 12:31 HKT/SGT
|
|
|
Honda Opens "Honda Software Studio Osaka" as New Software Development Operation
Jun 26, 2025 13:30 JST
|
|
|
Honda Issues "Honda ESG Report 2025"
Jun 26, 2025 13:29 JST
|
|
|
Fujitsu's Uvance Wayfinders consulting empowers customers to evolve business foundations leveraging data and AI
Jun 26, 2025 11:00 JST
|
|
|
XCF Global and Continual Renewable Ventures Announce Memorandum of Understanding to Launch New Rise Australia, a SAF and HVO Platform Powered by XCF
Jun 26, 2025 09:30 HKT/SGT
|
|
|
Investing News Network Strengthens Australian Presence with Appointment of Industry Veteran John Phillips
Jun 26, 2025 00:39 HKT/SGT
|
|
|
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 21:27 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
